Alex brings more than 16 years of drug development expertise in multiple technologies, therapeutic indications and clinical phases involving small molecules, biologics, combination products and ATMPs. His contributions have been strategic – helping to position companies for future growth and operational optimisation – as well as scientific – through consulting biotech and pharmaceutical clients on preclinical and clinical development and market approval.
Prior to joining PrimeVigilance, Alex held regulatory affairs and compliance consultancy and leadership positions in small and mid-size CROs and has previously worked for organisations such as Biotronik AG and Vifor Pharma Ltd in Switzerland.
Alex commenced his career as a researcher at Carnegie Mellon University, USA, following his doctoral studies in macromolecular/organic chemistry at Lancaster University, UK.
+44 (0)1483 307920
+1 792 3740
United Kingdom (Head Office)
USA
Croatia
Germany
Czech Republic
Serbia
Poland
Japan
This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.